Received patent allowance for a TRPV4 antagonist in Korea. Eligible for patent allowance across all five major patent offices, strengthening the intellectual property portfolio. No direct impact on 2026 performance.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4579","jir_company_name":"Lacroria Therapeutics Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4579-20260902-01.pdf","jir_short_summary":"Received patent allowance for a TRPV4 antagonist in Korea. Eligible for patent allowance across all five major patent offices, strengthening the intellectual property portfolio. No direct impact on 2026 performance.","jir_summary":"### Key points of the news\nThe material patent application for the TRPV4 antagonist in Korea (application number 10-2022-7040115) has been allowed, positioning the company's intellectual property portfolio for protection across all five major patent offices. The target drug has TRPV4 antagonistic action and shows promise in ocular, pain, and inflammatory models. It is stated that there will be no impact on the 2026 fiscal year results.\n\n### Future IP strategy and R&D activities\nContinue collaborative research\u6210\u679c with Gifu Pharmaceutical University under industry-academia collaboration, aiming to strengthen the patent portfolio and enhance long-term corporate value. Scholarly\u6210\u679c such as 2023 publications and 2025 conference introductions will continue to be disclosed as indicators of potential value for the company.","jir_financial_highlights":"Patent allowance obtained: Korea (Unknown)\nFuture impact on performance: Unknown (Unknown)","jir_category":"","jir_hashtags":"#LacroriaTherapeutics, #IPStrategy","jir_key_figures":"Patent allowances: Korea\nPatent allowances across all five major patent offices\nDirect impact on performance: Unknown (stated no impact for the 2026 fiscal year)","jir_meta_title":"Lacroria Therapeutics \u2013 Korea patent allowance for TRPV4 antagonist | Strengthening long-term IP","jir_meta_description":"Lacroria Therapeutics has received a patent allowance for a TRPV4 antagonist in Korea. With examinations completed at five major patent offices, the intellectual property portfolio is strengthened, with no direct impact on the 2026 fiscal year results. Ongoing disclosure of industry-academia collaboration outcomes.","jir_og_title":"Lacroria Therapeutics \u2013 IP strengthened by Korea patent allowance; no impact on results","jir_og_description":"TRPV4 antagonist patent allowance in Korea. Ongoing disclosure of IP strategy and research\u6210\u679c aimed at long-term corporate value.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57587,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-110185","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n